About: A Study of Bevacizumab Plus XELOX/XELIRI for First-line Treatment in Unresectable Advanced Colorectal Cancer

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: A Study of Bevacizumab Plus XELOX/XELIRI for First-line Treatment in Unresectable Advanced Colorectal Cancer Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

clinical trial

Attributes	Values
rdf:type	Item
description	clinical trial (en) ensayu clínicu (ast) klinisch onderzoek (nl) клінічне випробування (uk)
rdfs:label	A Study of Bevacizumab Plus XELOX/XELIRI for First-line Treatment in Unresectable Advanced Colorectal Cancer (en) A Study of Bevacizumab Plus XELOX/XELIRI for First-line Treatment in Unresectable Advanced Colorectal Cancer (nl)
skos:prefLabel	A Study of Bevacizumab Plus XELOX/XELIRI for First-line Treatment in Unresectable Advanced Colorectal Cancer (en) A Study of Bevacizumab Plus XELOX/XELIRI for First-line Treatment in Unresectable Advanced Colorectal Cancer (nl)
name	A Study of Bevacizumab Plus XELOX/XELIRI for First-line Treatment in Unresectable Advanced Colorectal Cancer (en) A Study of Bevacizumab Plus XELOX/XELIRI for First-line Treatment in Unresectable Advanced Colorectal Cancer (nl)
title	wds:Q89154151-15913EDC-250E-404C-A061-F555F7307A6C
title	A Multicenter Phase II Clinical Study of Bevacizumab Combined With Biweekly XELOX/XELIRI Alternative First-line Treatment for Unresectable Advanced Colorectal Cancer (en)
end time	wds:Q89154151-4F534F53-4BF5-409F-B247-5A50123A5A4D
end time	2021-07-01 00:00:00Z (xsd:dateTime)
instance of	wds:Q89154151-918C62FA-3E6E-45C7-AA7A-556B34E3783B
instance of	clinical trial
start time	wds:Q89154151-C8B8B73C-4515-4AC9-B5E9-5A008E849AAC
start time	2019-09-01 00:00:00Z (xsd:dateTime)
research intervention	wds:Q89154151-91AB3996-C58D-4D72-A75F-E90F064958B9 wds:Q89154151-B4AB078C-32B4-4B37-A01C-BE3F84B087F5 wds:Q89154151-D3E8C90C-43A7-488C-A68F-F4FC818F4A8A wds:Q89154151-D555F190-8CB1-4DBF-82A1-E8EC56D9DB82
research intervention	irinotecan bevacizumab oxaliplatin capecitabine
minimum age	wds:Q89154151-1604F117-1790-444A-A3FE-6D88223F7307
minimum age	18 (xsd:decimal)
number of participants	wds:Q89154151-9E68DFEB-D08A-41BA-946E-38CE663AA919
number of participants	50 (xsd:decimal)
maximum age	wds:Q89154151-E88F2BC0-EF95-463C-9E14-5D02DB02A826
maximum age	75 (xsd:decimal)
study type	wds:Q89154151-F1C8A5DB-7FE1-4DBC-ABF0-48057D3913A9
study type	interventional study
ClinicalTrials.gov ID	wds:Q89154151-4E3419BD-8C59-4A52-9016-BEB4DB472667
ClinicalTrials.gov ID	NCT04324476
clinical trial phase	wds:Q89154151-252D8352-F368-415E-8CCF-48E3E5DEAE82
clinical trial phase	phase II clinical trial
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q89154151

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 190 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software